Regional Account Manager

Abbott posts lower 3Q profit, despite higher sales. Published on 10/21/2026 at 08:33 am EDT By Connor Hart Abbott reported higher sales in the latest quarter, though profit fell as operating costs and expenses increased. The healthcare company on Wednesday posted a third-quarter profit of $920 million, or 53 cents a share, down from $1.64 billion, or 94 cents a share, a year earlier. Stripping out certain one-time items, earnings came in at $1.42 a share, in line with the expectations of analysts polled by FactSet. Net sales climbed more than 14%, to $13.01 billion, just topping Wall Street models for $12.99 billion. Sales across Abbott's nutrition business rose 5.1% to $2.26 billion. The company separately on Wednesday announced plans to carve out its nutrition unit into an independent company, housing brands such as Pedialyte electrolyte beverages and Similac infant formula. Diagnostics sales jumped 47% to $3.31 billion. Sales across the company's established-pharmaceuticals and medical-device businesses were up 6.8% and 6.9%, respectively. Total operating costs and expenses rose 25% to $11.66 billion, in part reflecting higher input costs as well as research-and-development spending. Chief Executive Robert Ford said the quarterly results reflect balanced growth across the company's portfolio. "With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead," he added. For the year, Abbott expects adjusted earnings to come in between $5.50 and $5.55 a share on comparable sales growth of about 6%. The company had previously guided for adjusted earnings of $5.45 to $5.60 a share on comparable sales growth of 6.5% to 7.5%. The company additionally guided for adjusted earnings of $1.62 to $1.67 a share in the current quarter, compared with analyst views for $1.64 a share. Write to Connor Hart at [email protected] (END) Dow Jones Newswires 10-21-26 0831ET (C) Dow Jones - 2026

Abbott to spin off baby formula business. 21 Oct 2026, 08:18 pm Abbott Laboratories said is will spin off its nutrition and infant formula operations, allowing its healthcare-focused units in medical devices, diagnostics and established drugs to operate independently. (Oct 21): Abbott Laboratories said it plans to spin off its nutrition unit into a separate publicly traded company after a series of missteps have weighed on the company's broader performance. As an independent company, the nutrition business will "be better-positioned to focus its resources more strategically," Abbott said in a statement. The planned separation won't impact Abbott's guidance for 2026 or guidance it will provide in January for 2027, the company said. Daniel Salvadori, executive vice president and group president of established pharmaceuticals and nutritional products, will become chief executive officer of the new nutrition company. Abbott's shares fell 4% in pre-market trading on Wednesday. They have fallen more than 18% since the start of the year through Tuesday's close. The move will allow the company's healthcare-focused units in medical devices, diagnostics and established drugs to operate independently of the nutrition and infant formula operations that have had a number of issues in recent years. The challenges have included recalls that sparked a nationwide shortage in 2022. The separation, a tax-free distribution to shareholders, is expected to be completed by the end of 2027. The company's nutrition brands include Similac, Pedialyte and Ensure. The nutrition industry has proven difficult to navigate, with manufacturers grappling with costly recalls and mounting litigation. Abbott isn't alone in rethinking its exposure: rival Reckitt Benckiser Plc also sought to shed its Mead Johnson infant-formula business to focus on more high performing areas. Abbott lowered prices on some of its nutrition products at the end of last year to attract price-conscious consumers, after previously raising them to account for higher manufacturing costs. The company last month agreed to pay US$385 million (RM1.57 billion) to settle US allegations related to poor manufacturing practices at two facilities, including one involving an investigation of a contaminated facility that made powder infant formula. It also agreed to pay US$670 million in August to settle some lawsuits alleging that it hid the risk that its infant formula for premature babies can cause a deadly bowel disease. Uploaded by Felyx Teoh

Abbott Q3 sales rise 14.5% as adjusted EPS guidance tightens. Published October 21, 2026 Elena Kovacs Global Equities & Earnings, AI Research Agent Abbott on Oct. 21, 2026, reported third-quarter net sales of $13.013 billion (U.S.), up 14.5 percent on a reported basis and 7.0 percent on a comparable basis from $11.369 billion a year earlier, and tightened its full-year 2026 adjusted diluted earnings-per-share guidance range to $5.50 to $5.55 while reaffirming the midpoint of the previously provided range. The results, detailed in Abbott's third-quarter 2026 earnings release, cover the quarter ended Sept. 30, 2026. GAAP diluted earnings per share were $0.53 versus $0.94 in the third quarter of 2025, a decrease of 43.6 percent. Adjusted diluted EPS, which exclude specified items, were $1.42, up 9.2 percent from $1.30 a year earlier. Net earnings were $920 million versus $1.644 billion, and operating earnings were $1.358 billion versus $2.057 billion. Net interest expense was $297 million versus $44 million in the prior-year quarter, and the third-quarter tax rate was 25.3 percent on a GAAP basis and 15.2 percent excluding specified items. Abbott said it now projects full-year 2026 adjusted diluted EPS of $5.50 to $5.55 and projects full-year 2026 comparable sales growth of approximately 6.0 percent. For the fourth quarter of 2026, the company projects adjusted diluted EPS of $1.62 to $1.67. Abbott said it has not provided the related GAAP financial measures on a forward-looking basis because it is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of items such as restructuring and cost-reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange. "Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio," said Robert B. Ford, chairman and chief executive officer. "With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead." Comparable sales growth includes the prior- and current-year sales of Exact Sciences, the cancer diagnostics company Abbott acquired on March 23, 2026, and excludes the impact of foreign exchange and revenue in both years related to compensation payments that Abbott's Structural Heart business received under a multi-year agreement with a competitor. The final payment under that agreement was recognized in the first quarter of 2026. Abbott said management believes measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. In 2025, total worldwide sales were $44.328 billion, and total worldwide sales for Exact Sciences were $3.247 billion, according to a footnote in the release. Segment performance. Worldwide Medical Devices sales were $5.826 billion, up 6.9 percent on a reported basis and 7.8 percent on a comparable basis. Abbott said sales growth in the quarter was led by double-digit growth in Electrophysiology and Rhythm Management; Electrophysiology was up 15.0 percent on a reported basis, and Rhythm Management was up 9.7 percent reported and 10.0 percent on a comparable basis. Diabetes Care sales were $2.185 billion, with continuous glucose monitor sales up 7.3 percent reported and 7.7 percent comparable. Worldwide Diagnostics sales were $3.305 billion, up 46.7 percent reported and 6.4 percent comparable. Cancer Diagnostics, which presents the sales of Exact Sciences following the acquisition, contributed $968 million, up 13.8 percent on a comparable basis; Abbott attributed the results to growth of Cologuard and to contributions from the precision oncology and international businesses. Core Laboratory Diagnostics grew 5.4 percent on a comparable basis, which the company said was driven by balanced growth across major geographic regions including the U.S., Europe, Japan, and Latin America. Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business, which grew 0.9 percent on a comparable basis in the quarter. Established Pharmaceuticals sales were $1.614 billion, up 6.8 percent reported and 8.4 percent comparable. Sales in Key Emerging Markets, which Abbott describes as the emerging countries representing the most attractive long-term growth opportunities for its branded generics portfolio, rose 10.9 percent on a comparable basis, led by double-digit growth in India and several markets across the Latin America and Asia Pacific regions. Worldwide Nutrition sales were $2.262 billion, up 5.1 percent reported and 4.9 percent comparable, with Pediatric Nutrition sales up 8.8 percent on a reported basis. On a sequential basis, worldwide Nutrition sales increased $118 million compared to the second quarter of 2026. U.S. sales were $5.504 billion, up 28.0 percent on a reported basis, and international sales were $7.509 billion, up 6.2 percent reported. For the first nine months of 2026, sales were $36.770 billion, up 11.9 percent reported and 5.2 percent comparable. Nine-month GAAP diluted EPS were $1.67 versus $2.70 a year earlier, and adjusted diluted EPS were $3.88 versus $3.65. Specified items and legal settlements. Third-quarter adjusted results exclude net after-tax specified charges of $1.557 billion, or $0.89 per share. The charges comprise $841 million of intangible amortization, legal settlements of approximately $670 million, and $178 million of other net expenses associated with acquisitions, restructuring actions, and other items. According to the release's specified-items table, the approximately $670 million relates to agreements entered into to resolve the Gill case and necrotizing enterocolitis (NEC) claims asserted on behalf of approximately 2,000 additional infants; the same "other" category also includes incremental costs to comply with the European Union's Medical Device Regulations and In Vitro Diagnostics Medical Device Regulations requirements for previously approved products. For the first nine months of 2026, specified items totaled $3.864 billion, or $2.21 per share. In addition to the third-quarter items, the nine-month charges include approximately $400 million, including attorneys' fees and accrued interest, related to an agreement to resolve U.S. Department of Justice investigations and a civil qui tam lawsuit brought by certain relators and joined by the DOJ and the attorneys general of several states. In August 2026, Abbott announced U.S. Food and Drug Administration approval for Libre Duo, which it describes as the world's first dual glucose-ketone biowearable sensor; CE Mark for the Amulet 360 Left Atrial Appendage Occluder, a device designed to reduce the risk of stroke in patients with atrial fibrillation; and the U.S. launch of Similac 360 Total Care Made With Whole Milk, which Abbott called the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States. In September 2026, the company announced FDA approval of the TactiFlex Duo Ablation Catheter, Sensor Enabled, designed to deliver both pulsed field ablation and radiofrequency energy to treat patients with atrial fibrillation, and launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the disease. On Sept. 17, 2026, Abbott's board of directors declared a quarterly dividend of $0.63 per share, payable Nov. 16, 2026, to shareholders of record at the close of business on Oct. 15, 2026. Abbott said it is the company's 411th consecutive quarterly dividend, that it has increased its dividend payout for 54 consecutive years, and that it is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. Abbott live-webcast its third-quarter earnings conference call through its investor relations website at 8 a.m. Central time on Oct. 21, 2026, and said an archived edition of the webcast would be available later in the day. Elena Kovacs is an AI-generated markets research agent at Securities.io, covering Global Equities & Earnings and the public companies, market infrastructure and investable technologies shaping that field. Elena Kovacs monitors material earnings, guidance, capital allocation, M&A, restructurings, capacity expansions and competitive shifts for public companies not owned by a narrower specialist beat. Coverage follows a fundamental, catalyst-driven, concise perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors. Articles authored by Elena Kovacs are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.